Just over half of Americans would definitely get vaccinated against the coronavirus, a new survey found

anti vaccine protest coroanvirus

Only half of Americans (55%) say they would get vaccinated against the novel coronavirus, if and when a vaccine becomes available, according to a new YouGov survey.
Another 26% said they were unsure about getting innoculated, while one in five said that they not get vaccinated at all.
The poll comes at a time where more than 100 potential coronavirus vaccines in development and health experts are emphasizing that a vaccine will be needed to return life to normal.
The sentiments echo another more recent survey by Reuters, which shows that a quarter of Americans have little or no interest in taking a vaccine.
Some participants however have said that their opinion might change, if the Food and Drug Administration (FDA) or scientific studies proved that the vaccine was safe to take.
Visit Business Insider’s homepage for more stories.

While health experts say a vaccine to prevent further coronavirus infection is needed to return life to normal, just over half of Americans say they would get vaccinated against the disease, a new poll found.

According to the survey, conducted by YouGov and Yahoo News, 55% of Americans said they will get vaccinated for the virus “if and when a coronavirus vaccine becomes available.”

In contrast, 26% said they were “unsure” about whether they would get a vaccination, while 19% said they do not plan to be vaccinated at all.

The survey was conducted between May 4 and 5 and used a sample of 1,574 adults. It comes at a time when scientists are racing to find a vaccine for the virus, which has so far infected more than 5 million people worldwide.

  A personal-finance YouTube creator, who would film videos in his car, shares how he turned his channel into a business that earned $220,000 last year in ad revenue

At the time of writing, there are more than 100 potential coronavirus vaccines in development.

This week, the US Department of Health and Human Services (HHS) announced that it would be working with the pharmaceutical company AstraZeneca to produce at least 400 million doses of AZD1222 — a potential COVID-19 vaccine.

Meanwhile, the head of the Oxford Vaccine Group, Andrew Pollard, said on Friday that clinical trials of its coronavirus vaccine candidate were “progressing well.”

While these breakthroughs have been significant, no vaccine is ready for publid deployment yet, and it will likely be some time before one is.

Similar sentiments about COVID-19 vaccination were echoed in another survey conducted by Reuters/Ipsos this week. The poll found that a quarter of Americans have little or no interest in being vaccinated against …read more

Source:: Business Insider

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *